coat protein complex I subunit gamma 2Genealiases: 2-COP · gamma-2-COP
Q-omics provides the consensus-scored COPG2 profile across patient tissues and cancer cell-line models. COPG2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, COPG2 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, COPG2 RNA expression shows 18,668 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, KIRP, and THYM as cancer lineages where COPG2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COPG2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COPG2 survival associations across molecular data types. COPG2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COPG2 RNA expression–survival associations across cancer types. High COPG2 expression shows unfavorable associations in CESC, KICH, LIHC and BLCA, but favorable associations in BRCA and UCS. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for COPG2 RNA expression.
This table summarizes COPG2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for COPG2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COPG2 shows higher tumor expression in KIRP, BLCA, COAD, LIHC, LUSC and LUAD. The KIRP box plot shows higher COPG2 RNA expression in tumor versus normal tissue (log2 FC = +0.901, t-test p < 0.001).
This table shows molecular features associated with COPG2 in patient tissues and cancer cell lines. In patient samples, COPG2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, COPG2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and CNS.
